Mar 31, 2020
Lannett Begins Marketing Generic Adderall® XR
Jan 24, 2020
Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*
Dec 19, 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Dec 12, 2019
Lannett To Commence Marketing Generic Adderall® XR
Nov 27, 2019
Visiongain Launches Report Examining the Potential in the $17bn Attention Deficit Hyperactivity Disorder Drugs Market
Jul 08, 2019
EIP Pharma Appoints Noel Donnelly as CFO
Jul 05, 2019
ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia
Jun 19, 2019
Global Hereditary Angioedema (HAE) Markets, 2017-2018 & 2019-2026
May 29, 2019
Servier Showcases Robust Presence at ASCO 2019
May 09, 2019
Servier Cuts Ribbon on New Boston Headquarters
Oct 23, 2018
Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn's Disease
Sep 26, 2018
Key Treatments and Latest Medical Advancements Reshaping Cardiovascular Drugs Market for Increasing Gains
Sep 25, 2018
Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating
Sep 20, 2018
Merrimack Receives $5 Million Milestone Payment from Shire
Aug 24, 2018
Shire Announces Cash Tender Offers for up to $2,250,000,000 Outstanding Principal Amount of Notes
Aug 17, 2018
2018 Mucopolysaccharidosis Disorders Drug Development Pipeline Review
Aug 07, 2018
Global Genes® Announces RARE Champion of Hope Award Recipients to be Honored at RARE Patient Advocacy Summit
Jun 08, 2018
Fabry's Disease Pipeline Analysis 2018: Major Players are Actelion Pharmaceuticals, Sanofi, Amicus Therapeutics, Protalix and Shire
Jun 06, 2018
Shire launches screen responsibly, an eyelove® initiative dedicated to prioritizing eye health in a screen-saturated world
May 30, 2018
Asia-Pacific Hereditary Angioedema (HAE) Therapeutics Markets 2016-2018 & 2023